Sichenzia Ross Friedman Ference LLP Represents DelMar Pharmaceuticals, Inc. in $5.6 Million Sale of Series B Preferred Shares
Press Release – New York, NY – May 5, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm represented DelMar Pharmaceuticals, Inc. in connection with the sale of $5,600,000 of its Series B Preferred Shares. DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments.
The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia and David Manno and associate Jeff Cahlon.
About Sichenzia Ross Friedman Ference LLP
Sichenzia Ross Friedman Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals.